FILING ANALYSIS · WEDNESDAY, NOVEMBER 18

Voyager Therapeutics, Inc. VYGR — 8-K/A: Results of Operations and Financial Condition

neutral

Voyager Therapeutics reported third quarter 2026 financial results with a cash position of $132 million, extending its cash runway into Q2 2028, and announced upcoming clinical milestones, including the expected dosing of VY1706 in the next few months and tau PET imaging efficacy data from the VY7523 trial in Q4 2026.

The filing

8-K/A - Voyager Therapeutics, Inc. (0001640266) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+